Why DexCom's latest earnings matter for investors

DexCom (DXCM) just reported first quarter 2026 results, with revenue of US$1.192b and net income of US$199.5m, alongside higher margins and updated profitability guidance that put cash generation and product momentum in focus.

Despite the strong first quarter update and profitability guidance, DexCom's recent share price performance has been weak. The 90 day share price return shows a 12.95% decline and the 1 year total shareholder return reflects a 28.63% loss, pointing to fading momentum even as earnings and cash generation remain in focus.

If DexCom's earnings story has you rethinking where growth in healthcare technology could come from next, it may be worth scanning for other specialised healthcare AI opportunities via the 35 healthcare AI stocks.

With revenue at US$1.192b, rising profits and upgraded margin guidance set against a 1 year total return loss of 28.63%, are you looking at an undervalued CGM leader or a stock where markets already price in future growth?

Most Popular Narrative: 27.1% Undervalued

With DexCom last closing at $60.91 and the most followed narrative pointing to a fair value of $83.54, the current pricing gap has caught a lot of attention.

The recent expansion of insurance reimbursement for type 2 non-insulin diabetes patients, now covering nearly 6 million lives across the three largest U.S. PBMs, opens a large, previously untapped segment of DexCom's addressable market, driving new patient growth and supporting robust multi-year revenue expansion.

Curious what kind of revenue build, margin profile, and valuation multiple are baked into that fair value gap? The full narrative spells out a detailed earnings path, share count assumptions, and the required P/E that ties it all together.

Result: Fair Value of $83.54 (UNDERVALUED)

However, you still need to weigh the risk that tighter Medicare pricing or stronger CGM competitors could pressure DexCom's margins and slow its growth ambitions.

Another View: What The P/E Is Telling You

Analysts see DexCom as about 27% undervalued with a fair value of $83.54. The current P/E of 25.3x is higher than both the US Medical Equipment industry at 24.1x and peers at 21.3x, while still below a fair ratio of 29.5x. This combination points to both upside potential and valuation risk if sentiment shifts.

To see how this valuation gap could close in practice, including the assumptions behind that higher fair ratio, take a closer look at our detailed multiple breakdown via the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly focused on whether DexCom's valuation gap is justified, it makes sense to move quickly, review the underlying drivers for yourself, and then see how they line up with the 4 key rewards

Looking for more investment ideas?

If DexCom has sharpened your focus on where to put fresh capital next, do not stop at one stock. Broaden your watchlist with targeted ideas now.

• Target potential mispricings by scanning 51 high quality undervalued stocks that combine quality fundamentals with room for a stronger market view.
• Strengthen your income stream by reviewing 12 dividend fortresses that pair 5%+ yields with an emphasis on resilience.
• Reduce portfolio stress by focusing on 71 resilient stocks with low risk scores built around balance sheet strength and lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.